FDA’s CDER un­veils de­tails of re­or­ga­ni­za­tion

The US Food and Drug Ad­min­is­tra­tion’s Cen­ter for Drug Eval­u­a­tion and Re­search (CDER) on Thurs­day an­nounced the de­tails of a ma­jor re­or­ga­ni­za­tion, af­fect­ing near­ly one-third of CDER.

The pro­posed re­or­ga­ni­za­tion will im­pact the Of­fice of New Drugs, Of­fice of Com­pli­ance, Of­fice of Ex­ec­u­tive Pro­grams, and Of­fice of Com­mu­ni­ca­tions and has been sub­mit­ted to HHS, though still must be ap­proved by HHS and sub­mit­ted to Con­gress for con­cur­rence. The changes will be in ef­fect once ap­proval is re­ceived and the 30-day con­gres­sion­al no­ti­fi­ca­tion has lapsed, FDA said.

FDA al­so not­ed that the changes are not part of a sep­a­rate ef­fort re­lat­ed to the New Drugs Reg­u­la­to­ry pro­gram Mod­ern­iza­tion, which is a longer-term ef­fort in­clud­ing a broad­er re­or­ga­ni­za­tion of OND.

Of­fice of New Drugs (OND)

The changes an­nounced Thurs­day in­clude the cre­ation of a new Of­fice of Ther­a­peu­tic Bi­o­log­ics and Biosim­i­lars (OTBB) with­in OND, which will house pol­i­cy staff and sci­en­tif­ic re­view staff. The re­struc­tur­ing will al­so re­align staff from the OND Im­me­di­ate Of­fice to the new OTBB and will help in im­ple­ment­ing the reau­tho­rized Biosim­i­lar User Fee Act (Bs­U­FA II).

“OTBB will give biosim­i­lar and in­ter­change­able prod­uct re­view a stronger in­fra­struc­ture with re­sources to stream­line and ad­vance pol­i­cy de­vel­op­ment,” FDA said. “The in­creas­ing com­plex­i­ties and vis­i­bil­i­ty of this pro­gram re­quire a ded­i­cat­ed of­fice to ef­fi­cient­ly and ef­fec­tive­ly achieve cross-or­ga­ni­za­tion­al co­or­di­na­tion and col­lab­o­ra­tion.”

Of­fice of Com­pli­ance (OC)

The Of­fice of Un­ap­proved Drugs and La­bel­ing Com­pli­ance will house the Di­vi­sion of Com­pound­ed Drugs, for­mer­ly known as the Di­vi­sion of Pre­scrip­tion Drugs.

“This change will bet­ter re­flect our crit­i­cal work re­lat­ing to com­pound­ing pol­i­cy and over­sight, as the di­vi­sion will ab­sorb the func­tions of the for­mer Com­pound­ing and Phar­ma­cy Prac­tice Branch. It will es­tab­lish three new branch­es re­lat­ing to com­pound­ing pol­i­cy, reg­u­la­to­ry ac­tions, and op­er­a­tions – and re­align the Pre­scrip­tion Drugs Branch with a new Di­vi­sion of Un­ap­proved New Drugs, for­mer­ly the Di­vi­sion of Non-Pre­scrip­tion Drugs & Health Fraud. New branch names will bet­ter re­flect the di­vi­sion’s mis­sion and goals,” FDA said.

In ad­di­tion, the Of­fice of Man­u­fac­tur­ing Qual­i­ty (OMQ) will es­tab­lish a third drug qual­i­ty di­vi­sion with two branch­es for glob­al com­pli­ance. And the Of­fice of Drug Se­cu­ri­ty, In­tegri­ty, and Re­sponse will re­name its Di­vi­sion of Im­ports, Ex­ports, and Re­calls to the Di­vi­sion of Glob­al Drug Dis­tri­b­u­tion and Pol­i­cy to re­flect the agency’s re­spon­si­bil­i­ty in en­sur­ing the safe­ty and qual­i­ty of drug prod­ucts flow­ing in­to and out of the US.

Of­fice of Ex­ec­u­tive Pro­grams (OEP)

OEP is re­struc­tur­ing to ad­dress the grow­ing vol­ume and com­plex­i­ty of man­ag­ing CDER’s ex­ec­u­tive pro­grams.
“The OEP changes will es­tab­lish four staff groups with­in OEP’s Im­me­di­ate Of­fice fo­cus­ing on spe­cial projects, ex­ec­u­tive sec­re­tari­at mat­ters, leg­isla­tive ac­tiv­i­ties, and pro­gram man­age­ment and analy­sis – ab­sorb­ing the func­tions of the for­mer Di­vi­sion of Ex­ec­u­tive Op­er­a­tions. The re­struc­tur­ing will al­so es­tab­lish two branch­es with­in the Di­vi­sion of Ad­vi­so­ry Com­mit­tee and Con­sul­tant Man­age­ment to man­age and over­see ad­vi­so­ry com­mit­tee and con­flict of in­ter­est mat­ters,” FDA said.

Of­fice of Com­mu­ni­ca­tions (OCOMM)

OCOMM’s changes in­clude es­tab­lish­ing three branch­es with­in the ex­ist­ing Di­vi­sion of Drug In­for­ma­tion. OCOMM will al­so re­name two di­vi­sions to bet­ter re­flect their ex­pand­ed mis­sion. The Di­vi­sion of Health Com­mu­ni­ca­tions will be­come the Di­vi­sion of Pub­lic Ed­u­ca­tion and Out­reach, and the Di­vi­sion of On­line Com­mu­ni­ca­tions will be­come the Di­vi­sion of Dig­i­tal and On­line Com­mu­ni­ca­tion.


First pub­lished here. Reg­u­la­to­ry Fo­cus is the flag­ship on­line pub­li­ca­tion of the Reg­u­la­to­ry Af­fairs Pro­fes­sion­als So­ci­ety (RAPS), the largest glob­al or­ga­ni­za­tion of and for those in­volved with the reg­u­la­tion of health­care and re­lat­ed prod­ucts, in­clud­ing med­ical de­vices, phar­ma­ceu­ti­cals, bi­o­log­ics and nu­tri­tion­al prod­ucts. Email news@raps.org for more in­for­ma­tion. 

Author

Zachary Brennan

managing editor, RAPS

Hal Barron, GSK

Break­ing the death spi­ral: Hal Bar­ron talks about trans­form­ing the mori­bund R&D cul­ture at GSK in a crit­i­cal year for the late-stage pipeline

Just ahead of GlaxoSmithKline’s Q2 update on Wednesday, science chief Hal Barron is making the rounds to talk up the pharma giant’s late-stage strategy as the top execs continue to woo back a deeply skeptical investor group while pushing through a whole new R&D culture.

And that’s not easy, Barron is quick to note. He told the Financial Times:

I think that culture, to some extent, is as hard, in fact even harder, than doing the science.

Endpoints News

Basic subscription required

Unlock this story instantly and join 55,100+ biopharma pros reading Endpoints daily — and it's free.

Some Big Phar­mas stepped up their game on da­ta trans­paren­cy — but which flunked the test?

The nonprofit Bioethics International has come out with their latest scorecard on data transparency among the big biopharmas in the industry — flagging a few standouts while spotlighting some laggards who are continuing to underperform.

Now in its third year, the nonprofit created a new set of standards with Yale School of Medicine and Stanford Law School to evaluate the track record on trial registration, results reporting, publication and data-sharing practice.

Busy Gilead crew throws strug­gling biotech a life­line, with some cash up­front and hun­dreds of mil­lions in biobucks for HIV deal

Durect $DRRX got a badly needed shot in the arm Monday morning as Gilead’s busy BD team lined up access to its extended-release platform tech for HIV and hepatitis B.

Gilead, a leader in the HIV sector, is paying a modest $25 million in cash for the right to jump on the platform at Durect, which has been using its technology to come up with an extended-release version of bupivacaine. The FDA rejected that in 2014, but Durect has been working on a comeback.

In­tec blitzed by PhI­II flop as lead pro­gram fails to beat Mer­ck­'s stan­dard com­bo for Parkin­son’s

Intec Pharma’s $NTEC lead drug slammed into a brick wall Monday morning. The small-cap Israeli biotech reported that its lead program — coming off a platform designed to produce a safer, more effective oral drug for Parkinson’s — failed the Phase III at the primary endpoint.

Researchers at Intec, which has already seen its share price collapse over the past few months, says that its Accordion Pill-Carbidopa/Levodopa failed to prove superior to Sinemet in reducing daily ‘off’ time. 

Cel­gene racks up third Ote­zla ap­proval, heat­ing up talks about who Bris­tol-My­ers will sell to

Whoever is taking Otezla off Bristol-Myers Squibb’s hands will have one more revenue stream to boast.

The drug — a rising star in Celgene’s pipeline that generated global sales of $1.6 billion last year — is now OK’d to treat oral ulcers associated with Behçet’s disease, a common symptom for a rare inflammatory disorder. This marks the third FDA approval for the PDE4 inhibitor since 2014, when it was greenlighted for plaque psoriasis and psoriatic arthritis.

Endpoints News

Basic subscription required

Unlock this story instantly and join 55,100+ biopharma pros reading Endpoints daily — and it's free.

Vlad Coric (Biohaven)

In an­oth­er dis­ap­point­ment for in­vestors, FDA slaps down Bio­haven’s re­vised ver­sion of an old ALS drug

Biohaven is at risk of making a habit of disappointing its investors.

Late Friday the biotech $BHVN reported that the FDA had rejected its application for riluzole, an old drug that they had made over into a sublingual formulation that dissolves under the tongue. According to Biohaven, the FDA had a problem with the active ingredient used in a bioequivalence study back in 2017, which they got from the Canadian drugmaker Apotex.

Apotex, though, has been a disaster ground. The manufacturer voluntarily yanked the ANDAs on 31 drugs — in late 2017 — after the FDA came across serious manufacturing deficiencies at their plants in India. A few days ago, the FDA made it official.

Endpoints News

Basic subscription required

Unlock this story instantly and join 55,100+ biopharma pros reading Endpoints daily — and it's free.

Francesco De Rubertis

Medicxi is rolling out its biggest fund ever to back Eu­rope's top 'sci­en­tists with strange ideas'

Francesco De Rubertis built Medicxi to be the kind of biotech venture player he would have liked to have known back when he was a full time scientist.

“When I was a scientist 20 years ago I would have loved Medicxi,’ the co-founder tells me. It’s the kind of place run by and for investigators, what the Medicxi partner calls “scientists with strange ideas — a platform for the drug hunter and scientific entrepreneur. That’s what I wanted when I was a scientist.”

Endpoints News

Basic subscription required

Unlock this story instantly and join 55,100+ biopharma pros reading Endpoints daily — and it's free.

Af­ter a decade, Vi­iV CSO John Pot­tage says it's time to step down — and he's hand­ing the job to long­time col­league Kim Smith

ViiV Healthcare has always been something unique in the global drug industry.

Owned by GlaxoSmithKline and Pfizer — with GSK in the lead as majority owner — it was created 10 years ago in a time of deep turmoil for the field as something independent of the pharma giants, but with access to lots of infrastructural support on demand. While R&D at the mother ship inside GSK was souring, a razor-focused ViiV provided a rare bright spot, challenging Gilead on a lucrative front in delivering new combinations that require fewer therapies with a more easily tolerated regimen.

They kept a massive number of people alive who would otherwise have been facing a death sentence. And they made money.

And throughout, John Pottage has been the chief scientific and chief medical officer.

Until now.

Endpoints News

Basic subscription required

Unlock this story instantly and join 55,100+ biopharma pros reading Endpoints daily — and it's free.

Chas­ing Roche's ag­ing block­buster fran­chise, Am­gen/Al­ler­gan roll out Avastin, Her­ceptin knock­offs at dis­count

Let the long battle for biosimilars in the cancer space begin.

Amgen has launched its Avastin and Herceptin copycats — licensed from the predecessors of Allergan — almost two years after the FDA had stamped its approval on Mvasi (bevacizumab-awwb) and three months after the Kanjinti OK (trastuzumab-anns). While the biotech had been fielding biosimilars in Europe, this marks their first foray in the US — and the first oncology biosimilars in the country.